Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial.

MLA

Branch-Elliman, Westyn, et al. “Subcutaneous Sarilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded Randomized Clinical Trial.” PloS One, vol. 17, no. 2, Feb. 2022, p. e0263591. EBSCOhost, https://doi.org/10.1371/journal.pone.0263591.

APA

Branch-Elliman, W., Ferguson, R., Doros, G., Woods, P., Leatherman, S., Strymish, J., Datta, R., Goswami, R., Jankowich, M. D., Shah, N. R., Taylor, T. H., Page, S. T., Schiller, S. J., Shannon, C., Hau, C., Flynn, M., Holmberg, E., Visnaw, K., Dhond, R., … Monach, P. A. (2022). Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PloS One, 17(2), e0263591. https://doi.org/10.1371/journal.pone.0263591

Chicago

Branch-Elliman, Westyn, Ryan Ferguson, Gheorghe Doros, Patricia Woods, Sarah Leatherman, Judith Strymish, Rupak Datta, et al. 2022. “Subcutaneous Sarilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded Randomized Clinical Trial.” PloS One 17 (2): e0263591. doi:10.1371/journal.pone.0263591.